Conditional siRNA Complexes Using Toehold Activation in Cardiac Hypertrophy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cardiac hypertrophy, a chronic condition leading to heart failure, lack cardiac-specific therapies with minimal adverse effects, as existing drugs targeting genes essential for disease progression also affect normal cells.
Innovation Solution
Development of conditional siRNA complexes (Cond-siRNAs) that remain inactive under normal conditions but activate upon interaction with cardiac-specific biomarkers, specifically targeting calcineurin and HDAC2 in diseased heart cells through toehold-mediated strand displacement.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing drugs targeting genes essential for disease progression are used, then therapeutic effect is improved, but off-target effects and side effects increase
Solution Approach 1:
The siRNA complex is designed with a sensor strand that confers condition-specific activity, making the therapeutic agent effective only in diseased cells expressing cardiac hypertrophy biomarkers while remaining inactive in normal cells, thus achieving local quality differentiation between healthy and diseased tissues
Solution Approach 2:
The patent changes the activity state parameter of the siRNA complex from constantly active to conditionally active by introducing a sensor strand that responds to biomarker presence, allowing the complex to switch between inactive and active states based on cellular conditions
2Measurement precision
If conditional siRNA complexes are designed with sensor strands, then specificity to diseased cells is improved, but molecular complexity increases
Solution Approach 1:
The patent merges the detection function (sensor strand binding to biomarker) and the therapeutic function (siRNA-mediated gene silencing) into a single integrated complex, where the sensor strand and siRNA strands work together as one molecular entity
Solution Approach 2:
The conditional siRNA complex serves multiple functions: it acts as both a detection system for cardiac hypertrophy biomarkers and a therapeutic agent for gene silencing, making one molecular construct perform both diagnostic and therapeutic roles
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Cond-siRNAs provide targeted RNA interference in diseased heart cells, minimizing off-target effects and side effects in other tissues by activating only in the presence of cardiac hypertrophy biomarkers, offering a precise therapeutic approach.
Implementation Method 1
The sensor strand is complementary to a biomarker associated with the pathological condition
Implementation Method 2
activate upon interaction with cardiac-specific biomarkers, specifically targeting calcineurin and HDAC2 in diseased heart cells through toehold-mediated strand displacement
Implementation Method 3
RNA interference (RNAi) is a sequence-specific mRNA degradation pathway mediated by siRNA duplexes
Data Source
AI summary
Disclosed herein are conditional siRNAs activatable by pro-hypertrophic RNA sequences and use thereof for treating conditions such as cardiac hypertrophy. The conditional siRNAs target calcineurin or HDAC2.